Regeneron Pharmaceuticals Inc. sell Bank of America Co.
Summary
This prediction ended on 18.04.26 with a price of €630.90. The price for Regeneron Pharmaceuticals Inc. massively increased, which is bad news for the SELL prediction by Bank_of_America_Co_. Bank_of_America_Co_ has a follow-up prediction for Regeneron Pharmaceuticals Inc., but this time predicts that Regeneron Pharmaceuticals Inc. is a Buy. Dividends of €3.58 are taken into consideration when calculating the performance. Bank_of_America_Co_ has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 2.374% | 2.374% | 42.969% |
| iShares Core DAX® | 0.437% | 5.640% | 7.806% |
| iShares Nasdaq 100 | 1.057% | 0.282% | 27.239% |
| iShares Nikkei 225® | 1.769% | 0.406% | 49.266% |
| iShares S&P 500 | 0.368% | 1.920% | 22.336% |
Comments by Bank_of_America_Co_ for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
In the thread Trading Regeneron Pharmaceuticals Inc.
Current prediction by Bank_of_America_Co_ for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
07.01.26
07.01.27
14.08.26
Stopped prediction by Bank_of_America_Co_ for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
12.04.24
12.04.25
13.04.25
Regeneron Pharmaceuticals Inc.
29.03.23
29.03.24
30.03.24

